Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study

Table 1 Baseline patients characteristics at enrollment, n (%)

	rhTPO (n = 35)	Control (n = 35)	P value1
Demographic
Sex			0.057
Male	32 (91.4)	26 (74.3)
Female	3 (8.6)	9 (25.7)
Age, mean ± SD, year	53.5 ± 10.9	50.1 ± 12.1	0.214
Etiology
Alcoholic liver disease	16 (45.7)	9 (25.7)	0.073
Hepatitis B	16 (45.7)	26 (74.3)
Hepatitis C	1 (2.9)	0 (0)
Non-alcoholic steatohepatitis	1 (2.9)	0 (0)
Autoimmune liver disease	1 (2.9)	0 (0)
Cirrhosis	26 (74.2)	21 (60.0)	0.203
Laboratory findings, median (Q1-Q3)
WBC, 109/L	2.5 (1.9, 5.3)	4.8 (3.1, 8.2)	< 0.001
Hemoglobin, g/L	108.0 (78.0, 121.0)	113.5 (98.0, 124.0)	0.228
Neutrophil, %	70.8 (63.5, 79.0)	78.7 (67.3, 87.2)	0.055
Platelet count, 109/L	28.0 (19.0, 39.0)	35.0 (24.0, 42.0)	0.130
Albumin, g/L	28.2 (24.4, 31.7)	27.5 (22.8, 31.8)	0.742
Alanine transaminase, U/L	34.0 (20.0, 71.0)	64.0 (35.0, 148.0)	0.003
Aspartate transaminase, U/L	59.0 (36.0, 106.0)	82.0 (45.0, 173.0)	0.152
Alkaline phosphatase, U/L	110.0 (88.0, 161.0)	70.5 (44.0, 140.0)	0.037
Gamma-glutamyl transferase, U/L	47.0 (22.0, 138.0)	113.0 (56.0, 212.0)	0.023
Total bilirubin, μmol/L	88.8 (76.3, 144.1)	113.9 (95.2, 132.7)	0.053
Creatinine, μmol/L	72.0 (59.0, 93.7)	64.0 (52.0, 81.0)	0.095
INR	1.7 (1.5, 2.1)	2.1 (2.0, 2.6)	0.088
MELD	17.0 (9.0, 22.0)	18.0 (13.8, 23.0)	0.187

¹P value indicates the comparison of variables between recombinant human thrombopoietin group and control group.

WBC: White blood cell count; INR: International normalized ratio; MELD: Model for end-stage liver disease; rhTPO: Recombinant human thrombopoietin.